MedPath
Found 862 clinical trials|View Analysis
Sort by:

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

Not Applicable
Not yet recruiting
Conditions
Melanoma Metastatic
Interventions
Radiation: Stereotactic Body Radiotherapy (extracranial) concurrent with immunotherapy
Drug: Immunotherapy alone
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
Melanoma Institute Australia
Target Recruit Count
129
Registration Number
NCT06767306
Locations
🇦🇺

Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Phase 1
Recruiting
Conditions
Melanoma
Interventions
Drug: PRJ1-3024
First Posted Date
2024-12-11
Last Posted Date
2024-12-11
Lead Sponsor
Zhuhai Yufan Biotechnologies Co., Ltd
Target Recruit Count
40
Registration Number
NCT06727630
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma

Not yet recruiting
Conditions
Metastatic Melanoma
First Posted Date
2024-11-28
Last Posted Date
2024-11-28
Lead Sponsor
Royal Marsden NHS Foundation Trust
Target Recruit Count
100
Registration Number
NCT06710093
Locations
🇬🇧

The Royal Marsden, Chelsea, London, United Kingdom

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Phase 1
Not yet recruiting
Conditions
Melanoma
Interventions
First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06683755
Locations
🇺🇸

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Tebentafusp-tebn With LDT in Metastatic UM

Phase 1
Not yet recruiting
Conditions
Metastatic Uveal Melanoma
Interventions
First Posted Date
2024-10-04
Last Posted Date
2024-10-14
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
109
Registration Number
NCT06626516
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Phase 2
Recruiting
Conditions
Metastatic Uveal Melanoma
Metastatic Uveal Melanoma in the Liver
Interventions
Drug: Tebentafusp
Radiation: TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
First Posted Date
2024-10-04
Last Posted Date
2025-01-08
Lead Sponsor
University of Miami
Target Recruit Count
30
Registration Number
NCT06627244
Locations
🇺🇸

University of Miami, Miami, Florida, United States

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1
Not yet recruiting
Conditions
Locally Advanced Cervical Carcinoma
Locally Advanced Colorectal Carcinoma
Locally Advanced Malignant Solid Neoplasm
Locally Advanced Melanoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Locally Advanced Renal Cell Carcinoma
Metastatic Cervical Carcinoma
Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Interventions
Biological: Aldesleukin
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Excisional Biopsy
Drug: Fludarabine
Procedure: Magnetic Resonance Imaging
Procedure: Standard Treatment
Biological: Therapeutic Tumor Infiltrating Lymphocytes
First Posted Date
2024-10-03
Last Posted Date
2024-10-03
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
12
Registration Number
NCT06626256
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)

Recruiting
Conditions
Melanoma Metastatic
First Posted Date
2024-09-06
Last Posted Date
2024-09-12
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Target Recruit Count
77
Registration Number
NCT06586593
Locations
🇫🇷

CHU Angers, Angers, France

🇫🇷

CHU de Besançon, Besançon, France

🇫🇷

Hôpital Avicenne, Bobigny, France

and more 6 locations

Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1

Completed
Conditions
Metastatic Melanoma
First Posted Date
2024-09-06
Last Posted Date
2024-09-06
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Target Recruit Count
18
Registration Number
NCT06586580
Locations
🇫🇷

CHU de Besançon, Besançon, France

© Copyright 2025. All Rights Reserved by MedPath